1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ARCHIVE
ARCHIVE
- Santen Signs Agreement with Koken for Dry Eye Products
June 10, 2002
- MEDICAL DEVICE NEWS IN BRIEF
June 10, 2002
- Kissei: Princeton Bonds Compromise Brings Profits Up
June 10, 2002
- CMIC to Be Listed on JASDAQ
June 10, 2002
- MBL Forms Strategic Alliance with Beckman Coulter
June 10, 2002
- Nikken Chemical: Sales Down 4.4% to \54.8 Bil.
June 10, 2002
- Interest in Generics Is Increasing: EMA President
June 10, 2002
- DIAGNOSTIC NEWS IN BRIEF
June 10, 2002
- Torii: Sales, Profits Down Due to Futhan Generics
June 10, 2002
- BUSINESS NEWS IN BRIEF
June 10, 2002
- WORLD NEWS IN BRIEF
June 10, 2002
- Toyama Chemical: Sales Down 22.7% Due to Slump of Mainstays
June 10, 2002
- Landiol for Tachyarrhythmia 1Recommended for Approval
June 10, 2002
- Tanabe's Mid-term Plan to Be Handed over to New President
June 3, 2002
- MEDICAL DEVICE NEWS IN BRIEF
June 3, 2002
- Sankyo, Sanwa Kagaku Tie Up on ARI, Ca Antagonist
June 3, 2002
- Combined Sales of 27 JPMA Member Firms Up 4.9% to \5,526 Bil.
June 3, 2002
- AstraZeneca, Shionogi to Comarket New Statin Crestor
June 3, 2002
- Yamanouchi: Sales Up 5.1% Thanks to Harnal, Lipitor
June 3, 2002
- Iressa to Be Approved in Japan before US, Europe
June 3, 2002
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…